Dr. Jennifer Buell
everyone. hello and Garo, much, very you Thank
there’s an review providing X this today. mentioned, that update As a on of and by we’ll slide AGENXXXX, summary program Garo I’ll start on
is of many to familiar you. molecule This
CTLA-X. multifunctional our it’s binds T-cell which As said, Garo antibody, to also
important the -- could this increased We engineered you is key Those increased molecule provide. this is with engineering immunogenicity, some we features molecule Fc this respond superior a as to treated. population. well potential CTLA-X, the combination polymorphism, as benefits about with X activation, or on safety features as patients did knew a XX% see PD-X, T-cell expect this genetic due responders, first slide respond the importantly, of engineered. region the of of see reduction which we endocrinopathies first-generation included a because generation of Now, beyond or will in population increase as we unlikely And such patients for to CTLA-X broaden patient impacts who to to
trial benefit you patients been patients this which what data this today, who will about to as our going AGENXXXX. And molecule are that genetic from harbor benefiting to show from the has we’re talk to designed polymorphism,
also We endocrinopathies, see side a the effects with very or to we of no related Yervoy that safety-related feature. have seen hypophysitis otherwise, none important
the Cell We’ve engineering important. quite that molecule engineered today, trials Fc Can something know And and to of similar from engineering. the is on we’re late-stage be last our Fc speak engineered margetuximab. Dhan as also We’ve we AGENXXXX year. with in HERX bring order published really our to this -- in We’ve that now techniques you also will we’ve shown molecule you technology supports benefit clinical on our to this data antibody TIGIT data called enhancements. seeing
some of aware You that of data. may be
dose-escalation see objective to profound like shown to AGENXXXX on has Phase a development. is unusual the next-generation which in in this responses, X activity early in So antibody This are clinical form X, trial. summarize slide advancing I’d of
and that therapy, trends hopeful durable as on patients to on current we’ll We’re patients continue that continue the responses. more see more based with
patient getting some of number as heard and converted as well access patients or patients could with COVID-XX, course have may to access clinical you been Now, cancer impact therapies. their this a trials treat with of hospitals to have that
interruption. to to this However, in of without spite reality, we continue our trials recruit
of have has waiting investigators principal that attributes today, informed queue patients supports AGENXXXX have be that continued this to-date, a data the enrolled. on of available And us enrollment Our trial. the to based lifesaving we
designed I safety and the efficacy was generation as of that remember, improve CTLA-X. to may first you Now, mentioned deliberately AGENXXXX earlier,
In that the of data supports to addition, expected now, population activity is molecule design that the and benefit. this patient I’m And seeing. we’re highlight who the to some expand antibody will going this
our escalation benefit demonstrated combination partial responses In AGENXXXX well disease clinical trial, of responses, patients with and of balstilimab as complete stabilization rate late-stage This as dose alone includes XX%. cancer. with in
prognostic unlikely and call, Now, the with therapy. the patient markers during very described patient’s refractory on a our late-stage These had cancer. patient she a patient patient last biomarker PDL-X, for all a we disease, that microsatellite us had had prior importantly respond out help negative poor This available to checked include determine based endometrial to likelihood first therapies with and therapies, her had negative to complete is patient a a responder these genetic CTLA-X. is spite which of to respond are rendered X at on AGENXXXX that to to disease, confirmed a monotherapy this patient CD-XX a that mg/kg. immune to odds, unlikely we In respond generation stable allele see her this in polymorphism thrilled
want very on locations here. to a with highlight is you endometrial another Now, patient case. see patient can multiple prognostic metastatic cancer, as refractory I This slide disease a with exciting profile poor in X, dose with AGENXXXX non-target a patient lesions in confirmed a response very-low lesion. PD-X combination of response and antibody. now in balstilimab, to This a target with also is This in her her our responded patient partial complete similarly
our now we convened slide Advisory Board. week your X. attention If I to turn with can Last
which session, Now, immuno-oncology review CTLA-X After some in the in whom we ago. dose specialists them XX generation this mechanism, are our years is endorsed AGENXXXX, for accelerated a first patients of of of speak. development as experts, first extensive top some an the comprised launching we process our of Advisory were now are Board to over with the CTLA-X advisors path
refractory market, cancers, is as cancer, available I the continue going or these prevalent updated effective limited of cancer progress phase you two endometrial, This we include there ago. treatment to that cell this fast-to-market development, strategy. PD-X PD-X These mature. These where pursue programs refractory well moments like few opportunities patients. For you as keep or just are said like commercial a which options as to opportunities. and large cases will with stable differently, shared melanoma these market are microsatellite colorectal tumors no We’ll highly non-small means tumors a and cancer after lung
program, now balstilimab, our our bali, which the PD-X call on CTLA-X we zali. the our for lead cancer slide X program show and which program The of turn evolution cervical see you we cancer. call therapies zalifrelimab, with to I’ll that results women
the presented now XX cohort on left data despite program, of VEGF chemotherapies median balstilimab our with on are widely a had and from Starting XX large based their we’ve still months zalifrelimab patients, which follow-up. benefit. are who of limited used of a that and The inhibitors,
review, which standard were in responses gold all cancer. outcomes by confirmed Importantly, in is independent radiology assessing a an
complete These patients so available is which XX newsletter, Agenus Notably, responses recent partial a have responses. in our rate in evaluated responses This findings X we response and objective XX these observed our summarized of a XX XX%. is We on website. far. include
a based As accelerated response with of rate XX%. approval in for XX their was antibody Merck a on PD-X granted reference, XX patients responses
see most with effective to our potential the As patients treatment you here, become can the has combination available metastatic to cancer. cervical
cancer disadvantaged backgrounds comments Patients a for patients from diagnosed horrifying And our who healthcare. regarding are economically plan. particularly access Cervical disease, and limited few young and is options cancer cervical women a with little cancer come to clinical with to a many progresses effects which effective chemotherapy, and as treatment and little then see can to available you here. them, has treated no toxic side Their difficult benefit. ultimately have
And trials this changing importantly, converting important importantly to shown patients with treatments. our cervical is currently convert that PD-X bali response. are from long-term importantly, progressing stabilization who + These antibodies, as later doubling to not reality. which responding, durable. we’re and clinical to responses, with once these disease compared our responses CTLA-X of Data for or cancer is has they’re us zali, patients to Agenus patients. most incredibly a near are committed We’re seeing also the available And
the year-end continue and metastatic relapsed/refractory submit recent keep we’ll on you cancer. FDA for to alone received Fast and mentioned from in investigation our zalifrelimab with informed this designation we combination We balstilimab call, of the filings to we BLA in progress. plan our or cervical that our During Track year
few Now, wrap exciting up with programs. I’m very going to
During research I agree. our recent I-O. they productive engine the meeting we experts, noted in clinical most have that with
Dhan leading here today. to joined very Chand about Dr. programs iNKT by clinic responsible our talk our lead respectively. our these expected for us and and of [indiscernible] programs I’m They’re next joining soon. our Dr. Today, are the scientists to TIGIT innovation enter two
different as antibodies, As to a up two TIGIT partner shaping you PD-X with know, tumor designed expressing approaches optimally powerful in is We’ve TIGIT. combination TIGIT. target especially
difficult-to-treat in T-cell our And potent TIGIT and antagonists. where or Fc bispecific antibodies has tested ineffective. activation killing our LAG-X AGENXXXX, is a when tumor anti-TIGIT combined monotherapy has showed superior antibodies all outperformed molecule First, cancers demonstrated antibody competitor with PD-X which PD-X are alone engineered
TIGIT with to allogeneic In advancing we to to rapidly treat to these treat addition antibodies, the cancer COVID-XX. two patients patients are clinic our and cell with therapy
And working both through to which joined INDs Beth that, us from fact, is clear [Indiscernible] as expect a tell as more to applications, molecular health Center. be trained is has like you cleared FDA us, been immunology shortly. Medical She as in will one this the matter the crisis. this may We Harvard week. during note Deaconess heartening she biology T-cells. I Israel and early weekends process of very about and
